Drug developer C4X shares fly after signing £330m AstraZeneca licensing deal big pharma Drug developer C4X Discovery has signed an exclusive licensing agreement worth up to $402m (£334m) with pharma giant AstraZeneca to develop oral therapy to treat inflammatory diseases. London-listed C4XD’s shares have rocketed this morning, up nearly 40 per cent to 28.5p so far. As part of the deal, C4XD will receive pre-clinical milestone payments worth up [...]
AstraZeneca’s battle against cancer knocks on door of EU with three new drugs new medicines AstraZeneca, the pharmaceutical giant behind one of the world’s first Covid-19 vaccines, has had three new cancer drugs recommended for approval in the European Union. The FTSE 100 pharma firm said its drug Imfinzi – for uses against biliary tract cancer alongside chemotherapy, gastric cancer medicine Enhertu and prostate cancer treatment Lynparza, in combination with [...]
AstraZeneca boss urges UK government to invest in medicines of the future big pharma The chief of AstraZeneca has urged the UK government to invest in the medicines of the future, as the regulatory environment for pharma in the US grows tougher. With the UK’s upcoming budget, CEO Pascal Soriot called on the government to protect the funding for innovative treatments as the long-term outlook for the healthcare industry [...]
Investors bet on AstraZeneca’s experimental breast cancer drug following positive trial October 26, 2022 Shares rose in AstraZeneca today on the back of progress made with its breast cancer treatment, which combines its older Faslodex drug with a new experimental offering. Breast cancer is the most common cancer in the world, with around 2.3 million patients diagnosed with the disease in 2020. It follows a disappointing result in a [...]
AstraZeneca asthma drug misses key marker in late-stage trial October 25, 2022 AstraZeneca’s asthma drug failed to significantly improve difficulties swallowing in a late-stage trial, the pharmaceutical giant announced today. The drug, called Fasenra, met just one of two main goals of a stage III study assessing the treatment’s benefits in a chronic allergic condition that causes difficulty in swallowing. The condition, eosinophilic esophagitis, is characterised by [...]
Drop in Covid-19 vaccine demand swings Oxford Biomedica to a loss September 15, 2022 A drop in Covid-19 vaccine demand and manufacturing has swung British biotech firm Oxford Biomedica to a revenue loss in the half of the year. The London-listed firm, which worked with AstraZeneca’s to produce its Covid-19 vaccine, has revenue slip more than 20 per cent to £64m in the six moths to 30 June, down [...]
AstraZeneca share price dips with investors ‘underwhelmed’ by diabetes drug August 30, 2022 AstraZeneca’s share price has dipped into the red today, with investors “underwhelmed” by its diabetes and heart failure drug Fraxiga. The stock sank 1.8 per cent to 11,160p per share by early afternoon. However, the share price has grown 6.2 per cent over the past three months. ‘’Investors appear to have been underwhelmed by the [...]
City Moves: Who’s switching jobs in the Square Mile? August 23, 2022 City A.M.’s Millie Turner provides a roundup of the most important hires and job moves across the City, every morning. Email citymoves@cityam.com to be featured. Knight Frank Property consultancy Knight Frank has appointed a new head of lettings in its King’s Cross office. Joining from the firm’s Canary Wharf office where he was a most recently an associate in the lettings team, [...]
GSK shares float above recent lows amid looming legal woes August 17, 2022 British pharmaceutical giant GlaxoSmithKline (GSK) has been wrapped up with legal woes this week over recalled heartburn drug Zantac and a former AstraZeneca dealmaker – which have wiped billions off its market value. London-listed GSK’s shares have dipped into the red slightly today but remained above recent lows. However, the company has lost nearly eight [...]
UK government must wake up to clinical research slowdown, industry body warns July 31, 2022 A slowdown in clinical research could hold Britain back in its bid to become a life sciences superpower, an industry body has warned. In a letter to Rishi Sunak and Liz Truss, the Association of the British Pharmaceutical Industry (ABPI) said “alarm bells” should be ringing across the government, the Sunday Telegraph reported. The letter [...]